Tanvex BioPharma Inc (泰福生技), which focuses on supplying safe and affordable biosimilars, has obtained marketing approval in Canada for its TX01, a biosimilar of Neupogen (filgrastim), the company said yesterday.
Tanvex has signed contracts with Canada-based Mint Pharmaceuticals Inc authorizing the firm to sell TX01 in Canada, it said in a statement.
It is not known when sales of the drug would begin, as discussions with importers are required first and the COVID-19 pandemic might disrupt distribution, Tanvex said.
The prices for TX01 have yet to be decided, as the company still has to negotiate with private insurers, it said.
The gap between the prices of brand drugs and biosimilars is smaller than between brand drugs and generic drugs, as biosimilars require more research and development, and are more complex than generic drugs, Tanvex said.
Sales in Canada of Neupogen and its biosimilars reached more than C$100 million (US$80.68 million) in the 12 months to June, Tanvex said.
Amgen Inc’s Neupogen is used to treat chemotherapy-induced neutropenia and decreases the incidence of infection caused by febrile neutropenia, the company said.
Amgen filed a patent infringement claim against Tanvex in July 2019, but Tanvex reached an agreement with Amgen in March last year.
The company declined to reveal how much it agreed to pay Amgen.
“The expense was lower than the legal expenses if we had chosen to continue engaging in a lawsuit with Amgen,” a company official said by telephone yesterday.
Tanvex said obtaining approval in Canada has made it more confident of receiving approval from the US Food and Drug Administration (FDA), adding that it applied for a biologics license with the agency in October 2018.
The company expects to gain approval from the US FDA in the third quarter of next year, it said.
Tanvex’s cumulative revenue totaled NT$560,000 (US$19,989) for the first three quarters, up 86 percent from a year earlier.
For the first two quarters, it registered a net loss of NT$793 million, less than its net loss of NT$1.17 billion a year earlier, company data showed.
Cairo’s new monorail slices across the city skyline, running above the familiar chaos of blaring horns and aging buses’ exhaust fumes that mark rush hour below. The US$4.5 billion monorail, opened this month, is among Egypt’s most prominent new transport projects, part of a debt-funded infrastructure drive criticized for sapping state finances while bringing limited benefits to most of the country’s 109 million people. “It feels like you’re in a different country,” said Ramy Sayed, a restaurant manager, aboard a driverless Innovia 300 train. “No noise, no traffic, we’re not used to this.” The eastern line runs 56km from the bustling middle-class
Taiwanese firms have increased investment in the Philippines in recent years as Manila’s ties with Washington deepen and global supply chains continue to shift away from China, an expert at the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The Philippines had not been among Taiwanese investors’ top choices in Southeast Asia, CIER Taiwan ASEAN Studies Center director Kristy Hsu (徐遵慈) said at a seminar in Taipei. However, Taiwan’s investment in the country has grown significantly since the COVID-19 pandemic, reaching US $257 million last year, a high in recent years, she said. Although Taiwan’s total investment in the Philippines still lags
Intel Corp regards Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) as a longstanding partner, as the US chipmaker would continue outsourcing production of advanced chips to TSMC, Intel chief executive officer Lip-Bu Tan (陳立武) said yesterday. “I don’t look at people as competitors. I look at the collaboration... Nvidia is also, you know, a good friend,” Tan told a news conference following his keynote speech at the Computex trade show in Taipei. “It’s a very trusted partnership for us... We are a big, top customer for them, and we’re going to continue doing that,” he said, referring to TSMC, the world’s largest foundry
Artificial intelligence (AI) agents would supplant smartphones as the center of people’s digital lives, fundamentally reshaping personal devices and driving a major computing upgrade cycle, Qualcomm Inc CEO Cristiano Amon said yesterday. In his keynote speech for this year’s Computex trade show in Taipei, Amon said that the rise of "agentic AI" — AI systems capable of reasoning, planning and carrying out tasks autonomously — would transform how people interact with technology across phones, PCs, vehicles and wearable devices. Describing the technology as the next major evolution in computing, Amon said that "2026 is the year of agents.” For decades, smartphones have sat
RSS